ALTO-101 Misses Primary Endpoint in Schizophrenia Trial, Company Shifts Focus to ALTO-207

ALTO-101 misses Phase 2 endpoints but shows signals. Alto pivots to ALTO-207 in treatment-resistant depression with strong prior data.